- Data on Successful Use of New PGD Technique to be Presented at American
Society for Reproductive Medicine (ASRM) Annual Meeting - - Improved Techniques Could Lead to Improved Overall Pre-natal Screening for Spontaneous Pregnancies as well as PGD with In Vitro Fertilization -
BUFFALO, N.Y., and LIVINGSTON, N.J., Oct. 15 /PRNewswire/ -- Empire Genomics, developing high throughput technologies that enable genome-wide analyses, and Reprogenetics, a genetics laboratory specializing in Preimplantation Genetic Diagnosis (PGD), announce data supporting a new technique to significantly improve the identification of genetic and chromosomal abnormalities from just a single or small group of embryonic cell(s). The microarray-based technology from Empire Genomics, tested and developed for in vitro fertilization in partnership with Reprogenetics, has multiple advantages when applied to PGD:
-- The test has the ability to screen all chromosomes - conventional
techniques typically selectively screen approximately half.
-- The test can be performed during the standard timeline of IVF with a
one day turnaround time.
-- It can successfully be performed with the genetic material of a single
-- It works rapidly and efficiently for preimplantation use with in vitro
The data will be presented jointly by Empire Genomics and Reprogenetics at the 63rd Annual Meeting of the ASRM in Washington, D.C. on Wednesday, October 17, 2007.
"We are convinced this new technology will enable us to improve
screening for genetic defects as well as improve the pregnancy outcome for
patients undergoing IVF by reducing spontaneous abortions and genetically
affected conceptions," said Santiago Munne, Ph.D., Reprogenetics director.
"Currently PGD requires highly skilled and experienced embryologists to
process the cells for the current technology. This new technology
simplifies this ste
Copyright©2007 PR Newswire.
All rights reserved